Kyntra Bio (KYNB) H.C. Wainwright 27th Annual Global Investment Conference summary

Strategic transactions and financial position

• Completed sale of China operations to AstraZeneca for $220 million, extending cash runway into 2028 and paying off $75 million debt.

• Simplified capital structure, eliminating significant debt overhang.

• Net cash from the sale includes $135 million held in China and a $10 million holdback expected within nine months.

Oncology pipeline: ADC targeting CD46 in prostate cancer

• Advancing an antibody-drug conjugate (ADC) targeting CD46, a novel, non-PSMA approach for metastatic castration-resistant prostate cancer (MCRPC).

• Phase 1 monotherapy trial showed 8.7 months median RPFS, 36% PSA 50 response, and 20% ORR at the 2.7 mg/kg dose.

• Phase 2 monotherapy trial to start imminently, with interim results expected in the second half of 2026.

• Companion PET imaging agent to inform patient selection; IND cleared last quarter.

• Ongoing IST at UCSF in combination with enzalutamide, with top-line results expected by year-end.

Clinical development strategy and trial design

• Phase 2 ADC trial will enroll 75 patients across three dose cohorts, using G-CSF prophylaxis to reduce neutropenia.

• Patient population will include earlier-line, pre-chemo MCRPC patients, expanding potential registration pathways.

• Phase 2 trial designed to select dose for phase 3 and explore both monotherapy and combination therapy options.